Acknowledgment of Financial Commercial Support No financial commercial support was received for this educational activity.
Acknowledgment of In-Kind Commercial Support No in-kind commercial support was received for this educational activity.
Satisfactory Completion Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Amedco LLC and National Hispanic Medical Association. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives - After Attending This Program You Should Be Able To
To increase knowledge about the health disparity challenges facing Hispanics and access to COVID -19 treatment.
To present an overview of Monoclonal Antibody Treatment for COVID-19 including eligibility of patients, infusion therapy, outcomes, and adverse effects, and research.
To discuss strategies and lessons learned from physicians at a monoclonal antibody treatment site for Hispanics and other vulnerable populations.
Disclosure of Conflict of Interest The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
Accreditation Statement